Glenmark:Margins expand - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark:Margins expand

Jun 11, 2002

Glenmark Pharmaceuticals Ltd, one of the leading pharma companies in dermatology segment (which deals with skin infections) has shown an impressive performance for the year ended March'02. While, sales have improved by 25%, operating margins have shown an improvement of more than 480 basis points, which is remarkable. However, higher interest and depreciation expenses diluted bottomline growth. The bottomline growth was still impressive at 34%.

(Rs m) FY01 FY02 % Change
Sales 1,923 2,402 24.9%
Other Income 21 16 -26.0%
Expenditure 1,624 1,915 17.9%
Operating Profit (EBDIT) 299 486 62.7%
Operating Profit Margin (%) 15.5% 20.3%
Interest 83 129 55.1%
Depreciation 51 88 73.0%
Profit before Tax 186 285 53.1%
Extraordinary Income - -
Tax 15 57 272.5%
Profit after Tax/(Loss) 171 228 33.5%
Net profit margin (%) 8.9% 9.5%  
No. of Shares (eoy) (m) 10.1 10.1  
Diluted Earnings per share* 16.9 22.6  
P/E (at current price) 7.2 12.0  
(*- annualised)      

Glenmark is a leader in the dermatology segment which contributed around 35% to its turnover. After the acquisition of Flucort (Lyka brand) the company also has considerable presence in the steroid segment of the dermatology market. The company has also identified the anti-diabetes market as a key growth area in future. A separate marketing force catering specifically to this market has also been set up, comprising an all-India sales force of 130 medical representatives.

The company's newly introduced division ‘Healtheon’ in the fast growing anti-diabetes market recorded impressive performance during the year. It may be recalled that the company has a tripartite agreement with Biobrass (the world’s third largest manufacturer of human and porcine insulin) and Ambalal Sarabhai to market insulin’s in the domestic market. Under the agreement Ambalal Sarabhai is importing insulin crystals from Biobrass to manufacture finished dosages and Glenmark is marketing the products.

Glenmark is striving to take a lead in research activities. In a significant development, the company has recently filed patent for a new anti-asthma drug, that is currently completing pre-clinical trials. The company has also initiated dialogues with various MNCs for collaborative research projects.

At the current market price of Rs 270, the stock is quoting at 12x its FY02 earnings. Given the initiatives taken by the company and focus on niche therapeutic segments one can expect the pace of growth to continue in future.


Equitymaster requests your view! Post a comment on "Glenmark:Margins expand". Click here!

  

More Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

I Believe These Stocks Will Deliver the Most Outsized Returns in 2021 and Beyond (Profit Hunter)

Sep 23, 2020

Rules of the racetrack can help you bag the biggest gainers of the coming decade.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 1, 2020 09:35 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS